知镜 Cognispect · 医学文献与研究工作台

Tracheal delivery of HO-1-modified human umbilical cord-derived mesenchymal stem cells treats pulmonary arterial hypertension by enhancing pulmonary antioxidant and anti-inflammatory responses.

Riken C, Xing C, Limei L, Huan L, Liping X, Dongjie H, Yong L, Deyi Z, Weilong Y, Shuyue Z, Yihuan S, Dekang N, Zhenzhen Z, Yan D.
Translational research : the journal of laboratory and clinical medicine · 2026-06-24 · PMID 42341913

文献摘要

Objective Pulmonary arterial hypertension (PAH) is a life-threatening cardiovascular disease, with current treatments only alleviating symptoms. Mesenchymal stem cells (MSCs) possess immune-regulatory and reparative properties, and HO-1-modified MSCs enhance their anti-inflammatory and antioxidant effects. This study aims to investigate the potential of tracheal delivery of HO-1-modified MSCs for the treatment of PAH. Methods This study first assessed the levels of inflammation and oxidative stress in the lung tissue pathology of healthy donors and IPAH patients, detecting F4/80, IL-6, and the oxidative stress marker 8-OHdG. Subsequently, in MCT-induced rat and hypoxia-exposed mouse models, we evaluated lung tissue sections for HE staining and α-SMA immunohistochemistry, along with antioxidant enzymes (SOD, CAT, GSH) and inflammatory factors (TNF-α, IL-18, IL-6, IL-1β) at 1, 2, 3, 4, and 5 weeks to assess the effects of various treatments. Next, we compared the anti-inflammatory and antioxidant capacities of HO-1-modified MSCs derived from umbilical cord (UC-MSCs) and adipose tissue (AD-MSCs), selecting the best cell intervention strategy. Using in vivo imaging, we assessed the cell homing of intravenously injected cells and drug retention after tracheal delivery. After tracheal delivery of HO-1-MSCs at 3, 4, and 5 weeks, we analyzed IHC staining for α-SMA, right heart catheterization, lung tissue inflammation, and antioxidant stress markers to identify the optimal intervention window. The efficacy was also compared with traditional HO-1 pharmacological agonists. Finally, the effects of HO-1-MSCs on vascular cells (PAECs, PASMCs) and immune cells (bone marrow macrophages, myeloid-derived neutrophils) in vivo were further explored to evaluate their potential and mechanisms in PAH treatment. Results Compared to donor controls, IPAH patient lung tissues exhibited significant inflammation and oxidative stress, with increased macrophage infiltration and elevated levels of IL-6 and 8-OHdG. In MCT rat and hypoxia mouse models, PAH development was associated with vascular remodeling, persistent inflammation, and oxidative stress. UC-MSCs showed stronger anti-inflammatory and antioxidant effects than AD-MSCs. Tracheal delivery of HO-1-MSCs significantly improved outcomes at weeks 3 and 4, reversing pulmonary vascular remodeling, reducing pulmonary artery pressure, inhibiting IL-6 and IL-18 expression, and restoring antioxidant enzyme activity (SOD and CAT). Compared to traditional HO-1 agonists, HO-1-MSCs demonstrated superior efficacy. Additionally, HO-1-MSCs effectively inhibited PAECs proliferation, suppressed the activation of the ERK/AKT pathway, reduced PASMCs proliferation and migration, significantly decreased neutrophil activation, and promoted M2 macrophage polarization while reducing the M1 macrophage population. Conclusion Tracheal delivery of HO-1-(UC)-MSCs effectively alleviates inflammation and oxidative stress in PAH, improves vascular remodeling and pulmonary artery pressure, and offers a promising new therapeutic strategy for PAH treatment.

在知镜精读原文来源DOI 原文

知镜提供医学文献检索、阅读笔记、人体图谱、统计绘图与研究复现工具。